

Zan Shen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6192426/publications.pdf>

Version: 2024-02-01

65
papers

1,246
citations

430874

18
h-index

395702

33
g-index

69
all docs

69
docs citations

69
times ranked

1923
citing authors

#	ARTICLE	IF	CITATIONS
1	Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 1766-1771.	1.2	257
2	Prognostic value of inflammation-based scores in patients with osteosarcoma. <i>Scientific Reports</i> , 2016, 6, 39862.	3.3	67
3	Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 394-403.	4.4	62
4	N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. <i>EBioMedicine</i> , 2020, 59, 102955.	6.1	61
5	Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 71-82.	4.4	60
6	Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. <i>Scientific Reports</i> , 2018, 8, 8537.	3.3	50
7	Bufalin suppresses the migration and invasion of prostate cancer cells through HOTAIR, the sponge of miR-520b. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1228-1236.	6.1	45
8	Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis. <i>Molecular Therapy</i> , 2016, 24, 1358-1368.	8.2	37
9	High-intensity focused ultrasound: Noninvasive treatment for local unresectable recurrence of osteosarcoma. <i>Surgical Oncology</i> , 2015, 24, 9-15.	1.6	36
10	Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1624-1633.	2.4	34
11	CD133 ⁺ CD44 ⁺ Cells Mediate in the Lung Metastasis of Osteosarcoma. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1719-1729.	2.6	30
12	CT Fluoroscopy-guided Percutaneous Osteoplasty for the Treatment of Osteolytic Lung Cancer Bone Metastases to the Spine and Pelvis. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1135-1142.	0.5	28
13	Heterogeneous expression and biological function of ubiquitin carboxy-terminal hydrolase-L1 in osteosarcoma. <i>Cancer Letters</i> , 2015, 359, 36-46.	7.2	26
14	Stereotactic radiosurgery, a potential alternative treatment for pulmonary metastases from osteosarcoma. <i>International Journal of Oncology</i> , 2014, 44, 1091-1098.	3.3	25
15	TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 23.	8.6	24
16	Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model. <i>BMC Cancer</i> , 2017, 17, 126.	2.6	21
17	Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro. <i>Biological Research</i> , 2017, 50, 15.	3.4	21
18	Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 270-275.	1.1	20

#	ARTICLE	IF	CITATIONS
19	KLF8 knockdown suppresses proliferation and invasion in human osteosarcoma cells. <i>Molecular Medicine Reports</i> , 2014, 9, 1613-1617.	2.4	19
20	D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment. <i>Molecular Therapy</i> , 2022, 30, 1188-1200.	8.2	19
21	Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma. <i>Current Therapeutic Research</i> , 2009, 70, 150-160.	1.2	17
22	Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. <i>Acta Pharmacologica Sinica</i> , 2012, 33, 832-838.	6.1	17
23	Comparison of pirarubicin-based versus gemcitabine+docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. <i>International Journal of Clinical Oncology</i> , 2013, 18, 498-505.	2.2	17
24	Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis. <i>European Journal of Cancer</i> , 2014, 50, 1125-1136.	2.8	17
25	H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma. <i>British Journal of Cancer</i> , 2018, 118, 522-533.	6.4	17
26	A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma. <i>Cancer Letters</i> , 2008, 272, 268-276.	7.2	15
27	Safety and efficacy of multilevel vertebroplasty for painful osteolytic spinal metastases: a single-centre experience. <i>European Radiology</i> , 2017, 27, 3436-3442.	4.5	14
28	Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients. <i>Scientific Reports</i> , 2017, 7, 17480.	3.3	13
29	Evaluation of pirarubicin+cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. <i>Medical Oncology</i> , 2012, 29, 2229-2233.	2.5	12
30	DGKZ Acts as a Potential Oncogene in Osteosarcoma Proliferation Through Its Possible Interaction With ERK1/2 and MYC Pathway. <i>Frontiers in Oncology</i> , 2018, 8, 655.	2.8	12
31	Accuracy of Tokuhashi score system in predicting survival of lung cancer patients with vertebral metastasis. <i>Journal of Neuro-Oncology</i> , 2015, 125, 427-433.	2.9	10
32	Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. <i>BMC Cancer</i> , 2019, 19, 1168.	2.6	10
33	Bilateral spontaneous pneumothorax in an osteosarcoma patient with pulmonary metastases: A case report. <i>Oncology Letters</i> , 2016, 11, 1179-1180.	1.8	9
34	Symptom interval of osteosarcoma around the knee joint: an analysis of 82 patients of a single institute. <i>European Journal of Cancer Care</i> , 2016, 25, 849-854.	1.5	7
35	Clinical Practice Guideline for Image-Guided Multimode Tumour Ablation Therapy in Hepatic Malignant Tumours. <i>Current Oncology</i> , 2019, 26, 658-664.	2.2	7
36	Relationship Between HSP70 and ERBB2 Expression in Breast Cancer Cell Lines Regarding Drug Resistance. <i>Anticancer Research</i> , 2016, 36, 1243-9.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells. <i>Molecular Medicine Reports</i> , 2014, 10, 2985-2992.	2.4	6
38	<scp>SKA</scp>1 induces <i>deÂNovo </i><scp>MTX</scp>â€resistance in osteosarcoma through inhibiting <scp>FPGS</scp> transcription. <i>FEBS Journal</i> , 2019, 286, 2399-2414.	4.7	6
39	Chromatin accessibility of CD8 T cell differentiation and metabolic regulation. <i>Cell Biology and Toxicology</i> , 2021, 37, 367-378.	5.3	6
40	Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute. <i>Oncology Letters</i> , 2014, 8, 2243-2248.	1.8	5
41	Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?. <i>Medical Oncology</i> , 2015, 32, 307.	2.5	5
42	Significance of HIFU in local unresectable recurrence of soft tissue sarcoma, a single-center, respective, case series in China. <i>Surgical Oncology</i> , 2019, 30, 117-121.	1.6	5
43	MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen. <i>International Journal of Oncology</i> , 2019, 54, 2019-2029.	3.3	5
44	Clinical significance of indeterminate pulmonary nodules on the survival of 364 patients with nonmetastatic, highâ€grade, localized osteosarcoma: A 12â€year retrospective cohort study. <i>Journal of Surgical Oncology</i> , 2021, 123, 587-595.	1.7	5
45	Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden. <i>Frontiers in Endocrinology</i> , 2021, 12, 625226.	3.5	5
46	Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis. <i>PLoS ONE</i> , 2017, 12, e0174668.	2.5	5
47	A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. <i>Cell Biology and Toxicology</i> , 2021, , 1.	5.3	5
48	A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 859958.	3.7	5
49	Elevated expression of serine/threonine phosphatase type 5 correlates with malignant proliferation in human osteosarcoma.. <i>Acta Biochimica Polonica</i> , 2017, 64, 11-16.	0.5	4
50	Impact of first-line treatment on outcomes of Ewing sarcoma of the spine. <i>American Journal of Cancer Research</i> , 2018, 8, 1262-1272.	1.4	4
51	Ailanthone Inhibits Proliferation, Migration and Invasion of Osteosarcoma Cells by Downregulating the Serine Biosynthetic Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 842406.	2.8	4
52	Comparison between preadolescent and adolescent patients with high-grade osteosarcoma in China. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 274-278.	0.1	3
53	Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma. <i>American Journal of Cancer Research</i> , 2015, 5, 411-22.	1.4	3
54	Fibrinogenâ€Albumin Ratio Index Exhibits Predictive Value of Neoadjuvant Chemotherapy in Osteosarcoma. <i>Cancer Management and Research</i> , 2022, Volume 14, 1671-1682.	1.9	3

#	ARTICLE	IF	CITATIONS
55	Retrospective clinical analysis of MAID protocol as first-line treatment on 137 metastatic soft-tissue sarcomas patients. Chinese-German Journal of Clinical Oncology, 2012, 11, 117-120.	0.1	2
56	The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma. OncoTargets and Therapy, 2021, Volume 14, 213-220.	2.0	2
57	Apatinib for patients with unresectable high-grade osteosarcoma progressing after standard chemotherapy: A multi-center retrospective study.. Journal of Clinical Oncology, 2017, 35, 11031-11031.	1.6	2
58	FAT1 and MSH2 Are Predictive Prognostic Markers for Chinese Osteosarcoma Patients Following Chemotherapeutic Treatment. Journal of Bone and Mineral Research, 2020, 37, 885-895.	2.8	2
59	Impacts of Pharmacists-Managed Oncology Outpatient Clinic on Resolving Drug-Related Problems in Ambulatory Neoplasm Patients: A Prospective Study in China. Inquiry (United States), 2021, 58, 004695802110096.	0.9	1
60	Impact of Secondary Aneurysmal Bone Cysts on Survival of Patients with Enneking Stage IIB Extremity Osteosarcoma: A Propensity Score Matching Analysis. Annals of Surgical Oncology, 2021, 28, 7864-7872.	1.5	1
61	The effectiveness of an independent anti-neoplastic medication therapy management system in ambulatory cancer patients. Translational Cancer Research, 2021, 10, 1703-1711.	1.0	1
62	Expression levels of CXCR4 and VEGF correlate with blood-borne metastatic progression and outcome in patients with osteosarcoma. Chinese-German Journal of Clinical Oncology, 2009, 8, 292-295.	0.1	0
63	Retrospective analysis of prognostic factors for sixty osteosarcoma patients with local recurrence. Chinese-German Journal of Clinical Oncology, 2013, 12, 123-128.	0.1	0
64	Promotion of proliferation and inhibition of apoptosis by diacylglycerol kinase zeta, a potential oncogene of osteosarcoma. Journal of Clinical Oncology, 2018, 36, e23503-e23503.	1.6	0
65	The timing of targeted therapy initiation in metastatic sarcoma as an adjuvant to first-line chemotherapy or a second-line agent. American Journal of Translational Research (discontinued), 2021, 13, 9095-9103.	0.0	0